Conversion surgery after induction therapy improves survival for advanced esophageal cancer patients

For patients with advanced esophageal cancer, the choice of treatment often feels like a gamble. A new analysis of 3,721 patients offers clearer hope. Those who received conversion surgery after initial therapy lived significantly longer than those who got definitive therapy alone. This approach boosted one-year survival from 49.6 percent to 73.6 percent. At three years, survival rose from 18.4 percent to 37.0 percent. By five years, the difference grew even wider, reaching 26.5 percent versus 11.6 percent. The benefit was especially strong for a specific subgroup with the most advanced disease, where one-year survival jumped from 37.6 percent to 86.4 percent. This analysis looked at data from many different sources to find these patterns. The results suggest that adding surgery to the treatment plan can make a real difference in how long people live. However, the researchers noted that the results for the most advanced disease group need more proof from larger studies. Until then, this data gives a strong signal that surgery may be the better path for many patients facing this difficult diagnosis.